OgilvyHealthPR wins Boehringer Ingelheim anti-clot drug brief

Pharma firm Boehringer Ingelheim has brought in OgilvyHealthPR as the global comms agency for its Pradaxa drug, which prevents blood clotting.

Pradaxa manufacturer: Boehringer Ingelheim's HQ
Pradaxa manufacturer: Boehringer Ingelheim's HQ

OgilvyHealthPR won the account following a competitive pitch and replaces Chandler Chicco Companies' medical education division Litmus. Pradaxa is an oral anticoagulant, used to prevent and treat acute and chronic thromboembolic disease.

OgilvyHealthPR will work with sister company Ogilvy Healthworld Digital to dev­elop and implement an integrated comms programme. Ogilvy Healthworld Digital is headed up by managing partners Caroline Howe and David Davenport-Firth.

Pradaxa is currently used in more than 50 countries for primary prevention of venous thromboembolic occurrences in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. It is also being investigated for the prevention of stroke in pat­ients with atrial fibrillation (abnormal heart rhythm).

The account will be led by OgilvyHealthPR business unit head Deanne Wallace, who is based in London.
OgilvyHealthPR already works on other global acc­ounts with Boehringer Ingelheim, including its diabetes portfolio.

Additionally, the agency has bolstered its senior team with the appointment of Ben Fisher as associate director. Fisher has ten years' experience in healthcare comms and joins the agency from Porter Novelli where he was an account director.

He will head up the Boeh­ringer Ingelheim diabetes portfolio, in addition to focusing on new business.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in